<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290691</url>
  </required_header>
  <id_info>
    <org_study_id>PJ-501-14</org_study_id>
    <nct_id>NCT02290691</nct_id>
  </id_info>
  <brief_title>Inactivated Influenza Via Jet Injection</brief_title>
  <acronym>IIJI</acronym>
  <official_title>Inactivated Influenza Via Jet Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaJet, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaJet, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the administration of flu vaccine using
      Needle-Free is equivalent to Needle and Syringe administration as measured by laboratory
      tests of immune response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary:

      To evaluate the non-inferiority of flu vaccine administered by needle-free intramuscular (IM)
      injection versus needle and syringe IM injection as determined with serum hemagglutination
      inhibition (HAI) reciprocal titers in healthy adults between 18-64 years.

      Secondary:

      To compare tolerability and safety of the vaccine in the same population based on
      specifically solicited local and systemic reactions occurring through 7 days
      post-immunization and adverse events spontaneously reported through approximately 28 days
      post immunization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti Influenza Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT)</measure>
    <time_frame>28 Days</time_frame>
    <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio (GMT with Needle-Free / GMT with Needle and Syringe) antigen will not exceed 1.5 fold.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titer.</measure>
    <time_frame>28 Days</time_frame>
    <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Immediate Complaints</measure>
    <time_frame>Day 0</time_frame>
    <description>The following possible immediate complaints will be solicited following the 30 minute safety observation period post-vaccination: local pain, redness, induration/swelling, itching where the injection was given. The data will be reported as &quot;immediate complaints&quot; and presumed to be related to the test article. Any other symptom experienced at 30 minutes will be recorded as an adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Solicited Local or Systemic Adverse Events</measure>
    <time_frame>7 Days</time_frame>
    <description>vaccine reactogenicity will be collected on a patient-completed diary card daily for seven days post-vaccination. The following adverse events will be solicited on the diary card: injection site pain, injection site tenderness, injection site itching, injection site swelling, injection site redness, injection site bruising, fever, fatigue, headache, nausea, chills, muscle ache.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Spontaneously Reported Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Subjects will be asked to report any other symptoms experienced in addition to the solicited &quot;immediate&quot; and &quot;vaccine reactogenicity&quot; events. Any other events reported will be tabulated as spontaneously reported adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">985</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>Needle- Free</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Needle and Syringe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Vaccine</intervention_name>
    <description>Influenza Vaccine</description>
    <arm_group_label>Needle- Free</arm_group_label>
    <arm_group_label>Needle and Syringe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged ≥ 18 and ≤ 64 years of age at time of enrollment

          -  Willing and able to give informed consent after reading the consent form and given
             adequate opportunity to discuss the study with the investigator or qualified designee

          -  Willing and able to adhere to all protocol required study procedures and to attend
             scheduled visits

          -  Able to receive the trivalent influenza vaccine (TIV) or quadrivalent influenza
             vaccine (QIV) based on PI judgment

          -  Stable health status with no exclusionary medical or neuropsychiatric conditions as
             determined during the screening evaluation and based on the clinical judgment of the
             investigator or qualified designee

          -  Access to a consistent means of telephone contact

        Exclusion Criteria:

          -  Presence of any febrile illness (oral temperature &gt;38 °C) on the day of immunization.
             Such subjects will be reevaluated for enrollment after resolution of illness

          -  Presence of significant acute or chronic uncontrolled medical or neuropsychiatric
             illness and /or presence of any significant condition that may prohibit inclusion as
             determined by the investigator or his qualified designee. Uncontrolled is defined as:
             requiring institution of a new treatment within 1 month prior to study enrollment or
             change in medication dosage in the month prior to study enrollment

          -  Any known immunosuppressive condition including: history of human immunodeficiency
             virus (HIV) infection, cancer or cancer treatment within 3 years of study enrollment,
             systemic glucocorticoids (in a dose ≥10 mg prednisone daily or equivalent for more
             than 7 consecutive days or for 10 or more days in total) within 1 month of study
             enrollment, or any other cytotoxic or immunosuppressive drug within 3 months of study
             enrollment. Any significant disorder of coagulation that would increase the risk of
             intramuscular injections or treatment with Coumadin derivatives or heparin

          -  Known or suspected to be allergic to eggs, chicken protein, neomycin, polymyxin or
             influenza vaccine

          -  History of severe or previous serious adverse reaction after an influenza vaccination

          -  Receipt of any immunoglobulin and/or blood products within 3 months of immunization or
             planned administration of any of these products during the study period

          -  Prior history of any demyelinating disease including Guillain-Barre syndrome.

          -  Presence of an active neurological disorder

          -  History of significant alcohol or drug abuse within one year prior to study enrollment

          -  Influenza vaccination or laboratory confirmed influenza infection within the previous
             six months before study vaccination or planned influenza vaccination during the study
             period

          -  Planned administration of any non-influenza vaccines 30 days prior to the study or
             during the study period

          -  Pregnant or plans to become pregnant during the study period

          -  Currently enrolled in another vaccine or drug study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Gannon, MD</last_name>
    <role>Study Director</role>
    <affiliation>PharmaJet, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Optimal Research LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research, LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research, LLC</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research, LLC</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>64614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Reserach, LLC</name>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <zip>46545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research, LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McAllister L, Anderson J, Werth K, Cho I, Copeland K, Le Cam Bouveret N, Plant D, Mendelman PM, Cobb DK. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial. Lancet. 2014 Aug 23;384(9944):674-81. doi: 10.1016/S0140-6736(14)60524-9. Epub 2014 May 31.</citation>
    <PMID>24881803</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <results_first_submitted>April 12, 2016</results_first_submitted>
  <results_first_submitted_qc>November 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 30, 2017</results_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Needle Free, Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were enrolled from 05 November 2014 to 15 January 2015 at six clinical centers in the United States.</recruitment_details>
      <pre_assignment_details>A total of 984 participants who met all inclusion criteria and not of the exclusion criteria were enrolled and vaccinated in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Needle- Free</title>
          <description>Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
        </group>
        <group group_id="P2">
          <title>Needle and Syringe</title>
          <description>Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="496"/>
                <participants group_id="P2" count="488"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="488"/>
                <participants group_id="P2" count="479"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Needle- Free</title>
          <description>Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
        </group>
        <group group_id="B2">
          <title>Needle and Syringe</title>
          <description>Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="496"/>
            <count group_id="B2" value="488"/>
            <count group_id="B3" value="984"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="496"/>
                    <measurement group_id="B2" value="488"/>
                    <measurement group_id="B3" value="984"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B3" value="496"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="255"/>
                    <measurement group_id="B2" value="233"/>
                    <measurement group_id="B3" value="488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti Influenza Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT)</title>
        <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio (GMT with Needle-Free / GMT with Needle and Syringe) antigen will not exceed 1.5 fold.</description>
        <time_frame>28 Days</time_frame>
        <population>Geometric mean titers of antibodies against the hemagglutinin (HA) antigens were assessed in the immunogenicity population.</population>
        <group_list>
          <group group_id="O1">
            <title>Needle and Syringe</title>
            <description>Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Needle- Free</title>
            <description>Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Anti Influenza Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT)</title>
          <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio (GMT with Needle-Free / GMT with Needle and Syringe) antigen will not exceed 1.5 fold.</description>
          <population>Geometric mean titers of antibodies against the hemagglutinin (HA) antigens were assessed in the immunogenicity population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="465"/>
                <count group_id="O2" value="473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/ H1N1 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="1.406"/>
                    <measurement group_id="O2" value="3.77" spread="1.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A H1N1 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.72" spread="1.109"/>
                    <measurement group_id="O2" value="5.70" spread="1.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="1.549"/>
                    <measurement group_id="O2" value="4.09" spread="1.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.04" spread="1.104"/>
                    <measurement group_id="O2" value="5.99" spread="1.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B1 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="1.128"/>
                    <measurement group_id="O2" value="2.94" spread="1.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B1 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" spread="1.102"/>
                    <measurement group_id="O2" value="4.25" spread="1.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="0.904"/>
                    <measurement group_id="O2" value="2.52" spread="0.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread="0.978"/>
                    <measurement group_id="O2" value="3.78" spread="1.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titer.</title>
        <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
        <time_frame>28 Days</time_frame>
        <population>Seroconversion against the hemagglutinin antigens contained in the vaccine were assessed in the Immunogenicity Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Needle and Syringe</title>
            <description>Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Needle- Free</title>
            <description>Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titer.</title>
          <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
          <population>Seroconversion against the hemagglutinin antigens contained in the vaccine were assessed in the Immunogenicity Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="465"/>
                <count group_id="O2" value="473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="457"/>
                    <measurement group_id="O2" value="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456"/>
                    <measurement group_id="O2" value="468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326"/>
                    <measurement group_id="O2" value="365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Immediate Complaints</title>
        <description>The following possible immediate complaints will be solicited following the 30 minute safety observation period post-vaccination: local pain, redness, induration/swelling, itching where the injection was given. The data will be reported as &quot;immediate complaints&quot; and presumed to be related to the test article. Any other symptom experienced at 30 minutes will be recorded as an adverse event.</description>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Needle and Syringe</title>
            <description>Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Needle- Free</title>
            <description>Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Immediate Complaints</title>
          <description>The following possible immediate complaints will be solicited following the 30 minute safety observation period post-vaccination: local pain, redness, induration/swelling, itching where the injection was given. The data will be reported as &quot;immediate complaints&quot; and presumed to be related to the test article. Any other symptom experienced at 30 minutes will be recorded as an adverse event.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="487"/>
                <count group_id="O2" value="496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6"/>
                    <measurement group_id="O2" value="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Solicited Local or Systemic Adverse Events</title>
        <description>vaccine reactogenicity will be collected on a patient-completed diary card daily for seven days post-vaccination. The following adverse events will be solicited on the diary card: injection site pain, injection site tenderness, injection site itching, injection site swelling, injection site redness, injection site bruising, fever, fatigue, headache, nausea, chills, muscle ache.</description>
        <time_frame>7 Days</time_frame>
        <population>Data included in the analysis were collected on a 7-Day Diary Card from the safety population and grade &gt;1.</population>
        <group_list>
          <group group_id="O1">
            <title>Needle and Syringe</title>
            <description>Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Needle- Free</title>
            <description>Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Solicited Local or Systemic Adverse Events</title>
          <description>vaccine reactogenicity will be collected on a patient-completed diary card daily for seven days post-vaccination. The following adverse events will be solicited on the diary card: injection site pain, injection site tenderness, injection site itching, injection site swelling, injection site redness, injection site bruising, fever, fatigue, headache, nausea, chills, muscle ache.</description>
          <population>Data included in the analysis were collected on a 7-Day Diary Card from the safety population and grade &gt;1.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="488"/>
                <count group_id="O2" value="496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7"/>
                    <measurement group_id="O2" value="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9"/>
                    <measurement group_id="O2" value="65.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                    <measurement group_id="O2" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Ache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6"/>
                    <measurement group_id="O2" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Spontaneously Reported Adverse Events</title>
        <description>Subjects will be asked to report any other symptoms experienced in addition to the solicited &quot;immediate&quot; and &quot;vaccine reactogenicity&quot; events. Any other events reported will be tabulated as spontaneously reported adverse events.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Needle and Syringe</title>
            <description>Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Needle- Free</title>
            <description>Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Spontaneously Reported Adverse Events</title>
          <description>Subjects will be asked to report any other symptoms experienced in addition to the solicited &quot;immediate&quot; and &quot;vaccine reactogenicity&quot; events. Any other events reported will be tabulated as spontaneously reported adverse events.</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="488"/>
                <count group_id="O2" value="496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5"/>
                    <measurement group_id="O2" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are reported based on participant recall of events over 28 days</time_frame>
      <desc>Spontaneously reported adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Needle- Free</title>
          <description>Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
        </group>
        <group group_id="E2">
          <title>Needle and Syringe</title>
          <description>Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
Influenza Vaccine: Influenza Vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="488"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 14.0">laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="488"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>influenza and pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="496"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="488"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="486" subjects_at_risk="496"/>
                <counts group_id="E2" subjects_affected="475" subjects_at_risk="488"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.0)">Pain</sub_title>
                <counts group_id="E1" events="236" subjects_affected="236" subjects_at_risk="496"/>
                <counts group_id="E2" events="160" subjects_affected="160" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="319" subjects_affected="319" subjects_at_risk="496"/>
                <counts group_id="E2" events="223" subjects_affected="223" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="118" subjects_affected="118" subjects_at_risk="496"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" events="173" subjects_affected="173" subjects_at_risk="496"/>
                <counts group_id="E2" events="39" subjects_affected="39" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="145" subjects_affected="145" subjects_at_risk="496"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="50" subjects_affected="50" subjects_at_risk="496"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="496"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="72" subjects_affected="72" subjects_at_risk="496"/>
                <counts group_id="E2" events="76" subjects_affected="76" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="58" subjects_affected="58" subjects_at_risk="496"/>
                <counts group_id="E2" events="72" subjects_affected="72" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>Muscle Ache</sub_title>
                <counts group_id="E1" events="99" subjects_affected="99" subjects_at_risk="496"/>
                <counts group_id="E2" events="103" subjects_affected="103" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="496"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="496"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="488"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="496"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="488"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor may invite Study's Investigators to participate in the preparation of a multicenter article for a professional journal; terms will be at the discretion of the sponsor. Investigators may also wish to publish, present, or use for instruction and research the results of the Study collected at their individual research sites only after publication of pooled, multicenter results and under the following conditions. Materials will be provided to Sponsor for approval prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tara Miller, MS, Clinical Affairs Manager</name_or_title>
      <organization>PharmaJet, Inc</organization>
      <phone>888-900-4321 ext 4163</phone>
      <email>tara.miller@pharmajet.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

